Medicaid Rebate Reform: A Sign Of Minimal Drug Pricing Threats Or A Warning Of More To Come?
Executive Summary
House Democrats push to remove the current limit on Medicaid rebates in upcoming COVID-19 relief package would likely leave many drug companies unscathed, but some expect bigger ticket drug pricing items will soon be on the agenda.
You may also be interested in...
Drug Pricing Reform In Medicaid: Watch This Space
Some manufacturers may have to start essentially paying Medicaid programs to cover their drugs beginning in 2024 under a provision in the US economic relief bill headed to President Biden.
As CMS Chief, Brooks-LaSure Could Turn Quickly To Medicare Drug Spending Reforms
Chiquita Brooks-LaSure would be in a key position to implement the Biden Administration’s drug pricing priorities and is familiar with the balancing act needed when considering competing interests among stakeholders as policies are shaped.
US Pharma Faces First Drug Pricing Fight Of 2021
A $16bn provision to increase rebates in the US Medicaid program is a surprise inclusion in the COVID relief package moving through Congress. It looks like an uphill fight for industry to stop it from happening.